August « 2014 « Science and Enterprise

Biotech, Institutes Discover Target for Multiple Tumors

By Alan, on August 14th, 2014%

EphA3 illustration (Protein Data Bank/Wikimedia Commons)

14 August 2014. Researchers in the U.S. and Australia identified an enzyme found in a range of cancerous tumor cells, but not normal adult tissue, and tested an engineered antibody to fight that enzyme in tumors. The team from the biotechnology company KaloBios Pharmaceuticals Inc. in South San . . . → Read More: Biotech, Institutes Discover Target for Multiple Tumors

Middle, Inner Ear Drug Developer Raises $100M in IPO

By Alan, on August 13th, 2014%

(VA.gov)

13 August 2014. Otonomy Inc., a biopharmaceutical company in San Diego developing treatments for disorders of the middle and inner ear, raised $100 million in its initial public offering of stock. The company, trading on the NASDAQ under the symbol OTIC, priced its 6.25 million shares at $16.00.

Otonomy was founded in . . . → Read More: Middle, Inner Ear Drug Developer Raises $100M in IPO

Genetically Engineered Medflies Found to Control Wild Types

By Alan, on August 13th, 2014%

Mediterranean fruit fly (Oxitec Ltd.)

13 August 2014. Researchers at the biotechnology company Oxitec Ltd. in Oxford and University of East Anglia in Norwich, both in the U.K., created a modified form of the Mediterranean fruit fly that tests show can reduce the population of this pest responsible for extensive crop damage in . . . → Read More: Genetically Engineered Medflies Found to Control Wild Types

23andMe, Pfizer Partner on Bowel Disease Genetics

By Alan, on August 12th, 2014%

(Genome.gov)

12 August 2014. The pharmaceutical company Pfizer and personal genetics company 23andMe in Mountain View, California are researching genetic factors associated with inflammatory bowel disease, for which Pfizer is testing several treatments. Financial aspects of the collaboration were not disclosed.

Inflammatory bowel disease is the name given to disorders of the digestive . . . → Read More: 23andMe, Pfizer Partner on Bowel Disease Genetics

Heart Assn Challenge Seeks Heart Disease Prevention Tools

By Alan, on August 11th, 2014%

(NASA.gov)

11 August 2014. American Heart Association seeks new products to better prevent and manage heart disease and stroke in an open-innovation challenge for early-stage companies in the Midwest. The top three winners will be eligible for awards of up to $20,000, and a chance to pitch their ideas at a November forum . . . → Read More: Heart Assn Challenge Seeks Heart Disease Prevention Tools

Licensing Deal Combines Genomics, Placenta Stem Cells

By Alan, on August 11th, 2014%

(Michelle Tribe, Flickr)

11 August 2014. A new licensing agreement will make available research by Celgene Cellular Therapeutics on stem cells from the placenta to Human Longevity Inc., a company specializing in genomics for age-related disorders. Financial aspects of the agreement were not disclosed, but as part of the deal, Celgene is expected . . . → Read More: Licensing Deal Combines Genomics, Placenta Stem Cells

Trial Shows Stem Cell Treatment Feasibility for Stroke

By Alan, on August 8th, 2014%

CT scan of stroke victim’s brain (National Library of Medicine)

8 August 2014. An early-stage clinical trial shows treating stroke patients with their own bone-marrow stem cells is safe and feasible, and provides evidence of improving cognitive and motor functions. The study conducted by Imperial College London and affiliated hospitals in the U.K. . . . → Read More: Trial Shows Stem Cell Treatment Feasibility for Stroke

Graphene Sensor Designed for Wearable Disease Detection

By Alan, on August 7th, 2014%

First author Girish Kulkarni, left, and Zhaohui Zhong testing the graphene sensor (Joseph Xu, University of Michigan)

7 August 2014. Engineers at University of Michigan in Ann Arbor designed a sensor from graphene that makes it possible to embed the technology into wearable devices for disease detection. The team from the labs of . . . → Read More: Graphene Sensor Designed for Wearable Disease Detection

Efficient Sequencing Method Devised to ID Cells, Biomarkers

By Alan, on August 6th, 2014%

(Univ of California, San Francisco)

6 August 2014. Researchers at University of California in San Francisco and Fluidigm Corp. in South San Francisco developed a more efficient process for analyzing genetic material, still revealing cell types and biomarkers that previously required more in-depth analysis. The team led by Arnold Kriegstein, director of UCSF’s . . . → Read More: Efficient Sequencing Method Devised to ID Cells, Biomarkers

Immunotherapy Start-Up Adds $134M in Venture Funding

By Alan, on August 5th, 2014%

T-cell (NIAID/NIH)

5 August 2014. Juno Therapeutics, a biotechnology company in Seattle developing cancer treatments that harness the human immune system, secured $134 million in its second round of venture financing. The company, a spin-off enterprise from research labs in Seattle and New York, says the new round was provided by 10 public . . . → Read More: Immunotherapy Start-Up Adds $134M in Venture Funding

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise